OverviewSuggest Edit

Spero Therapeutics is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The Company’s pipeline of anti-infective agents is one of the most unique in the industry. Spero is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens.
TypePublic
Founded2013
HQCambridge, MA, US
Websitesperotherapeutics.com
Employee Ratings5

Latest Updates

Employees (est.) (Dec 2019)57(+40%)
Revenue (FY, 2020)$9.3 M(-48%)
Share Price (Jun 2021)$14.2(-2%)
Cybersecurity ratingAMore

Key People/Management at Spero Therapeutics

Ankit Mahadevia

Ankit Mahadevia

President and CEO
Milind Deshpande

Milind Deshpande

Chairman of the Board
Thomas Parr

Thomas Parr

Chief Scientific Officer
Cristina Larkin

Cristina Larkin

Chief Operating Officer
David Melnick

David Melnick

Chief Medical Officer
Troy Lister

Troy Lister

Vice President of Research
Show more

Spero Therapeutics Office Locations

Spero Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
675 Massachusetts Ave
Show all (1)

Spero Therapeutics Financials and Metrics

Spero Therapeutics Revenue

Spero Therapeutics's revenue was reported to be $9.33 m in FY, 2020
USD

Revenue (FY, 2020)

9.3m

Net income (FY, 2020)

(78.3m)

EBIT (FY, 2020)

(79.1m)

Market capitalization (4-Jun-2021)

419.3m

Closing stock price (4-Jun-2021)

14.2

Cash (31-Dec-2020)

85.2m

EV

342.1m
Spero Therapeutics's current market capitalization is $419.3 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.0m18.1m9.3m

General and administrative expense

10.8m12.9m15.6m21.4m

R&D expense

32.9m33.9m65.8m67.0m

Operating expense total

43.7m46.8m81.4m88.4m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

463.0k658.0k7.7m2.2m4.6m1.7m1.7m4.0m

General and administrative expense

3.7m3.0m3.1m3.1m3.9m3.8m4.1m4.1m4.5m5.3m

R&D expense

6.9m8.9m7.4m8.5m9.5m12.0m18.5m20.4m15.7m17.7m

Operating expense total

10.6m12.0m10.4m11.6m13.4m15.8m22.6m24.5m20.2m23.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

87.3m34.1m29.7m85.2m

Accounts Receivable

1.0m376.0k7.8m5.3m

Prepaid Expenses

1.8m7.5m4.8m6.1m

Current Assets

92.1m124.2m95.4m139.1m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

25.4m52.6m48.7m40.5m49.4m71.1m45.6m64.4m65.3m125.2m

Accounts Receivable

537.0k1.2m794.0k332.0k456.0k2.1m5.0m2.7m4.0m7.1m

Prepaid Expenses

1.0m1.2m1.2m1.2m7.9m6.3m3.7m5.7m9.2m7.3m

Current Assets

27.0m79.7m70.5m133.7m115.7m112.7m104.0m98.0m85.3m142.7m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(39.9m)(41.7m)(60.9m)(78.3m)

Depreciation and Amortization

363.0k409.0k750.0k

Accounts Payable

2.3m84.0k564.0k(3.0m)

Cash From Operating Activities

(39.1m)(39.6m)(50.0m)(85.9m)
Quarterly
USDQ3, 2017

Financial Leverage

-0.4 x
Show all financial metrics

Spero Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Spero Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Spero Therapeutics Online and Social Media Presence

Embed Graph

Spero Therapeutics News and Updates

Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206

The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206 The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206

Spero Therapeutics to Participate at the Berenberg Conference USA

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare…

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

Tebipenem HBr advancing towards NDA submission in the second half of 2021

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and ra…

Spero Therapeutics to Present at Investor Conferences in March

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rar…

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rar…
Show more

Spero Therapeutics Blogs

Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update Content Import Thu, 05/06/2021 - 16:02 Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update May 06, 2021 This release is a backfill from …

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and

Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update

Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance Conference call and live webcast at 4:30 p.m. EST  today CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical

Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

CAMBRIDGE, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and

Spero Therapeutics to Present at Investor Conferences in September

CAMBRIDGE, Mass. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and

Spero Therapeutics Announces Proposed Public Offering

Spero Therapeutics Announces Proposed Public Offering Content Import Wed, 09/09/2020 - 16:33 Spero Therapeutics Announces Proposed Public Offering September 09, 2020 This release is a backfill from a News Wire General CAMBRIDGE, Mass., Sept. 09, 2…
Show more

Spero Therapeutics Frequently Asked Questions

  • When was Spero Therapeutics founded?

    Spero Therapeutics was founded in 2013.

  • Who are Spero Therapeutics key executives?

    Spero Therapeutics's key executives are Ankit Mahadevia, Milind Deshpande and Thomas Parr.

  • How many employees does Spero Therapeutics have?

    Spero Therapeutics has 57 employees.

  • What is Spero Therapeutics revenue?

    Latest Spero Therapeutics annual revenue is $9.3 m.

  • What is Spero Therapeutics revenue per employee?

    Latest Spero Therapeutics revenue per employee is $163.7 k.

  • Who are Spero Therapeutics competitors?

    Competitors of Spero Therapeutics include Respicardia, Tactile Medical and GAIA.

  • Where is Spero Therapeutics headquarters?

    Spero Therapeutics headquarters is located at 675 Massachusetts Ave, Cambridge.

  • Where are Spero Therapeutics offices?

    Spero Therapeutics has an office in Cambridge.

  • How many offices does Spero Therapeutics have?

    Spero Therapeutics has 1 office.